Fundraising Fox

Invea Therapeutics, Inc.

Guilford, US · Founded 2021 · Delaware corporation · 1 known investors

inveatx.com ↗

Invea Therapeutics is a biotechnology company developing small molecule oral therapies for immune-mediated inflammatory diseases using artificial intelligence and machine learning to understand inflammation mechanisms. The company targets patients with chronic IMIDs through innovative drug candidates including lead program INVA8001.

AI & Machine LearningBiotechin /invea-therapeutics

Founders & leadership

KNKrishnan Nandabalan
Krishnan NandabalaninChief Executive Officer, President and Chairman
SA
Salvatore AlesciChief Scientific Officer
AKAman Kant
Aman KantinChief Operating Officer
MJ
Michael J. AielloChief Financial Officer
""
"Shunichiro ""Steve""" OkadaExecutive Officer
SL
Sandeep LaumasDirector
VM
Vimal MehtaDirector
DK
Demetrios KydonieusDirector
KB
Kerrie BradyDirector
SD
Stephen DobersteinDirector
JZ
Jonathan ZalevskyDirector

Investors · 1

Connecticut InnovationsNew Haven · $500K – $2M

Reported raises · per SEC filings

Form D private placements
▶$120.3KraisedDec 2025 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Demetrios KydonieusDirector
  • Aman KantExecutive Officer
  • Salvatore AlesciExecutive Officer
  • Michael J. AielloExecutive Officer
  • Jonathan ZalevskyDirector
  • "Shunichiro ""Steve""" OkadaExecutive Officer
  • Stephen DobersteinDirector
  • Kerrie BradyDirector
  • Krishnan NandabalanExecutive Officer, Director
Offering amount
$120.3K
Amount sold
$120.3K
Minimum investment
$10K
First sale
Oct 2025
Incorporated
Corporation, Delaware, 2021
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$300KraisedApr 2025 · 2 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Krishnan NandabalanExecutive Officer, Director
  • Salvatore AlesciExecutive Officer
  • Demetrios KydonieusDirector
  • Kerrie BradyDirector
  • Aman KantExecutive Officer
  • Stephen DobersteinDirector
  • Jonathan ZalevskyDirector
  • "Shunichiro ""Steve""" OkadaExecutive Officer
  • Michael J. AielloExecutive Officer
Offering amount
$600K
Amount sold
$300K
Minimum investment
$10K
First sale
Mar 2025
Incorporated
Corporation, Delaware, 2021
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.5MraisedApr 2022 · 4 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Salvatore AlesciExecutive Officer
  • Jonathan ZalevskyDirector
  • "Shunichiro ""Steve""" OkadaExecutive Officer
  • Aman KantExecutive Officer
  • Sandeep LaumasDirector
  • Demetrios KydonieusDirector
  • Vimal MehtaDirector
  • Michael AielloExecutive Officer
  • Krishnan NandabalanExecutive Officer, Director, Promoter
  • Kerrie BradyDirector
Offering amount
$5.8M
Amount sold
$1.5M
First sale
Apr 2022
Incorporated
Corporation, Delaware, 2021
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.